GlaxoSmithKline (GSK), the world’s second biggest drug maker, said it was interested in acquisitions in India if the assets came at the right value. The attempt would be to acquire brands and improve its consumer healthcare business, but not assets that sell pure generics (low cost, high volume business), said Andrew Witty, global CEO.
Speaking to reporters at Nashik (Maharashtra) where GSK dedicated a filariasis drug manufacturing facility today to WHO’s ‘Global programme to eliminate lymphatic filariasis’, Witty said the company would also be interested in adding to its vaccine manufacturing capacities in the country.
http://www.business-standard.com/india/news/glaxo-interested-in-indian-acquisitions/388001/